David K. Lee, CEO of Servier Pharmaceuticals, shared a post by Servier Pharmaceuticals on LinkedIn:
“Today, Servier announced the signing of the transaction to acquire Edgewise Therapeutics’ neuromuscular business. This milestone builds on our established mission in neurology, developing treatments for patients with rare neurological conditions, and brings potential first-in-class treatments into our pipeline.
Our team is excited about the opportunities that lie ahead. Following a similar strategy that we adopted in oncology nearly a decade ago, we have the experience needed to inform our work, and we will continue to build as we remain grounded in our patient-first operating model.”
Quoting Servier‘s post:
“Today, Servier announced the acquisition of Edgewise Therapeutics‘ neuromuscular business, a key step in accelerating our ambition in neurology.”
Other articles about Neurology on OncoDaily.